Sermorelin (also known as GRF 1-29 or GHRH 1-29) is a synthetic peptide consisting of the first 29 amino acids of naturally occurring human growth hormone-releasing hormone (GHRH). Developed in the 1980s, it became the first GHRH analog to receive FDA approval, marketed as Geref for diagnosing and treating growth hormone deficiency in children. Though the branded product was withdrawn from the U.S. market in 2008 for commercial reasons unrelated to safety, sermorelin remains one of the most extensively studied growth hormone secretagogues in clinical medicine. It continues to be prescribed through compounding pharmacies for age-related GH decline, body composition optimization, and anti-aging applications.
What Is Sermorelin?
Sermorelin is the biologically active N-terminal fragment of the 44-amino acid human GHRH molecule. Research in the early 1980s established that amino acids 1 through 29 of GHRH retain full biological activity at the pituitary GHRH receptor, making sermorelin the shortest fully functional fragment of the native hormone. Its amino acid sequence is: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂, with a molecular weight of approximately 3,358 Da.
The FDA approved sermorelin injection (0.05 mg/amp) under NDA 19-863 in December 1990 for diagnostic use, followed by approval of Geref (0.5 mg and 1.0 mg vials) under NDA 20-443 in September 1997 for the treatment of idiopathic growth hormone deficiency in children with growth failure. EMD Serono, the sole manufacturer, voluntarily ceased production in 2008 as recombinant human growth hormone (rhGH) dominated the pediatric GHD market, making Geref commercially unviable. The FDA formally withdrew NDA approval in June 2009 but confirmed in a 2013 Federal Register notice that the withdrawal was not for reasons of safety or effectiveness.
What distinguishes sermorelin from other GHRH analogs is its close structural identity to native GHRH. Unlike CJC-1295, which incorporates amino acid substitutions and (in its DAC form) an albumin-binding moiety to extend its half-life to days, sermorelin has a plasma half-life of only 11 to 12 minutes, producing brief, physiological pulses of GH release. Compared to tesamorelin, a 44-amino acid modified GHRH analog currently FDA-approved for HIV-associated lipodystrophy, sermorelin is smaller and less resistant to enzymatic degradation but has a longer clinical track record across a broader range of indications. See the sermorelin vs CJC-1295 comparison for a full breakdown of these two GHRH analogs.
Proposed benefits of sermorelin include:
- Stimulation of endogenous growth hormone production from the pituitary
- Increased IGF-1 levels and downstream anabolic signaling
- Improved body composition (increased lean mass, reduced body fat)
- Enhanced deep sleep (slow-wave sleep) architecture
- Improved skin thickness and collagen synthesis
- Preservation of the hypothalamic-pituitary feedback axis
- Potential improvements in insulin sensitivity and metabolic health
How It Works
GHRH Receptor Activation
Sermorelin binds to the growth hormone-releasing hormone receptor (GHRHR) on somatotroph cells in the anterior pituitary gland. The GHRHR is a G protein-coupled receptor that, upon activation, triggers the Gs/adenylyl cyclase/cAMP signaling pathway along with mitogen-activated protein kinase (MAPK) cascades. This stimulates both the synthesis and secretion of growth hormone from somatotroph cells.
Critically, sermorelin's GH-releasing effect is modulated by somatostatin, the hypothalamic inhibitory hormone that opposes GHRH signaling. When somatostatin tone is high (during waking hours and after meals), sermorelin's efficacy is reduced. When somatostatin tone naturally falls, particularly during early sleep, sermorelin's stimulatory effect is amplified. This interplay explains why bedtime administration is the standard protocol: it aligns exogenous GHRH stimulation with the body's natural window of maximal GH secretory potential.
Growth Hormone Cascade
Once growth hormone is released into the circulation, it binds to GH receptors in the liver, stimulating production of insulin-like growth factor 1 (IGF-1). IGF-1 mediates many of GH's downstream effects: protein synthesis in skeletal muscle, chondrocyte proliferation in cartilage, osteoblast activation in bone, and lipolysis in adipose tissue. Clinical studies of sermorelin in elderly adults have demonstrated significant increases in IGF-1 levels within 2 to 4 weeks of treatment, with IGF-1 remaining elevated throughout the treatment period.
The GH-IGF-1 axis also exerts broad metabolic effects, including improvements in lipid profiles, increased glucose disposal in skeletal muscle, and enhanced nitrogen retention, collectively contributing to the body composition changes observed with sustained sermorelin therapy.
Hypothalamic-Pituitary Axis Preservation
One of sermorelin's most important pharmacological advantages is its preservation of the hypothalamic-pituitary-somatotropic (HPS) axis. Exogenous GH administration delivers a constant, supraphysiological hormone load that suppresses endogenous GH production through negative feedback on both the hypothalamus and pituitary. Over time, this can cause somatotroph atrophy and prolonged suppression of natural GH secretion after discontinuation.
Sermorelin, by contrast, works upstream of the pituitary. It stimulates the same receptor that endogenous GHRH activates, and the resulting GH release remains subject to somatostatin-mediated negative feedback. The pituitary releases GH in its natural pulsatile pattern rather than the flat, sustained elevation produced by exogenous GH injections. Studies have shown that when sermorelin is discontinued, GH levels return to baseline without evidence of prolonged suppression. The pituitary's secretory capacity appears to be maintained or even restored in some cases.
Effects on Sleep Architecture
The relationship between GHRH and slow-wave sleep (SWS) is bidirectional. GHRH signaling promotes SWS onset and duration, while SWS itself creates the hormonal environment (low somatostatin, high GHRH tone) that facilitates the largest GH pulse of the 24-hour cycle. This nocturnal surge represents 60% to 70% of total daily GH secretion in men (the proportion is lower and more variable in women) and can reach concentrations 10 to 20 times higher than daytime levels.
Clinical studies have demonstrated that pulsatile GHRH administration during the first half of the night significantly increases both GH secretion and time spent in slow-wave sleep. Bedtime sermorelin injections leverage this physiology, reinforcing the natural nocturnal GH surge rather than disrupting circadian hormone patterns.
Dosage Protocols
Sermorelin dosing should be individualized by a licensed healthcare provider based on the patient's age, body weight, baseline IGF-1 levels, and treatment goals. The following ranges are derived from clinical literature and prescribing conventions at compounding pharmacies:
- Standard anti-aging and wellness range: 200 to 300 mcg administered subcutaneously at bedtime, 5 to 7 nights per week
- Conservative starting dose: 100 to 200 mcg at bedtime for the first 2 to 4 weeks, titrated upward based on tolerance and clinical response
- Higher-end clinical dosing: 300 to 500 mcg at bedtime, typically reserved for patients with documented low IGF-1 levels or poor initial response
- Pediatric dosing (historical FDA-approved): 30 mcg/kg subcutaneously at bedtime, as per the original Geref labeling
Most protocols employ 5-nights-per-week dosing (weekdays on, weekends off) to balance therapeutic benefit with physiological rest periods. Some providers prescribe nightly dosing for the first 3 to 6 months before transitioning to a 5-on/2-off schedule.
Cycling is not universally required with sermorelin due to its axis-preserving mechanism, but some clinicians recommend periodic reassessment (every 3 to 6 months) with IGF-1 monitoring to adjust dosing. Unlike GH secretagogues that act on the ghrelin receptor, tolerance to sermorelin's GHRH receptor activation appears to develop slowly, if at all.How to Use / Administration Methods
Sermorelin is administered via subcutaneous (SubQ) injection, typically into the abdominal fat pad, anterior thigh, or posterior upper arm.
Why bedtime dosing matters: The largest physiological GH pulse occurs during early slow-wave sleep, when hypothalamic somatostatin tone drops to its lowest point. Injecting sermorelin 15 to 30 minutes before bed synchronizes exogenous GHRH receptor stimulation with this natural secretory window, maximizing GH output. Administering sermorelin during the day, when somatostatin tone is high, substantially blunts the GH response.
Injection process:
- Reconstitute the lyophilized powder with bacteriostatic water (see Reconstitution section)
- Draw the prescribed dose into an insulin syringe (29 to 31 gauge, 0.5 or 1 mL)
- Clean the injection site with an alcohol swab
- Pinch a fold of skin and insert the needle at a 45 to 90 degree angle
- Inject slowly and steadily
- Withdraw the needle and apply gentle pressure with a clean swab if needed
Injection sites should be rotated to prevent lipodystrophy or local irritation. Administering on an empty stomach (at least 90 minutes after the last meal) is recommended, as elevated blood glucose and insulin can attenuate the GH response.
Results Timelines
Individual responses vary based on age, baseline GH and IGF-1 levels, body composition, diet, and exercise habits. The following timelines reflect patterns reported in clinical studies and prescriber experience:
Weeks 1 to 4:
- Improved sleep quality, including deeper sleep and more vivid dreams, is often the earliest reported benefit
- Mild increases in energy and daytime alertness
- Some users report improved mood and sense of wellbeing
Weeks 4 to 8:
- Measurable increases in serum IGF-1 levels (typically detectable by week 4 to 6)
- Improved recovery from exercise, with reduced soreness and faster return to baseline
- Early improvements in skin hydration, thickness, and elasticity
Months 2 to 6:
- Progressive improvements in body composition: increased lean mass (one study demonstrated a significant 1.26 kg increase in men) and reductions in body fat, particularly visceral adipose tissue
- Strength and exercise tolerance improvements
- Enhanced collagen production visible in skin quality, hair, and nail growth
- Continued improvement in sleep architecture
- One study in older adults showed a 35% increase in IGF-1 levels with 6 months of bedtime sermorelin injections
Maximum benefits are generally observed at the 3 to 6 month mark with consistent use. Clinicians typically reassess IGF-1 levels and clinical response at 3-month intervals to adjust dosing.
Research Evidence
Pediatric Growth Hormone Deficiency
The clinical data supporting sermorelin's efficacy in children is the most robust. In the pivotal studies supporting Geref's FDA approval, daily subcutaneous sermorelin increased growth velocity in 74% of children with idiopathic GHD after 6 months of treatment. Significant increases in height velocity were sustained during 12 months of treatment, with limited data suggesting maintained efficacy through 36 months of continuous therapy. Sermorelin induced catch-up growth in the majority of GH-deficient children, with the best responses in shorter children with delayed bone age.
Elderly Adults and Age-Related GH Decline
Vittone et al. (1997) conducted a 6-week study in 11 healthy men aged 64 to 76 years, administering 2 mg of subcutaneous sermorelin nightly. The study demonstrated a near-doubling of nocturnal GH output, though IGF-1 levels did not significantly increase over the short treatment period. In a separate, longer study of 19 adults aged 55 to 71, a 16-week randomized placebo-controlled trial demonstrated significant increases in nocturnal GH secretion and serum IGF-1 in both men and women. Men showed a significant increase in lean body mass (1.26 kg) and improved insulin sensitivity, while both sexes exhibited increased skin thickness.
A 6-month study combining daily bedtime sermorelin with exercise conditioning demonstrated IGF-1 increases of approximately 35% and favorable changes in body composition, including increased lean mass and decreased visceral abdominal fat.GH Stimulation Testing
Sermorelin has established utility as a diagnostic agent. Intravenous administration of sermorelin (1 mcg/kg) provides a rapid, relatively specific test for diagnosing GH deficiency, with fewer false-positive responses compared to other provocative tests such as insulin tolerance testing. This diagnostic application was part of its original FDA approval.
Limitations of the Evidence Base
While sermorelin's mechanism and acute GH-releasing effects are well characterized, several limitations should be acknowledged. The largest body of controlled human data comes from pediatric GHD populations, a different clinical context from adult anti-aging use. Adult studies have generally been small (fewer than 20 participants), short in duration (4 to 6 months), and focused on surrogate markers (IGF-1, body composition) rather than hard clinical endpoints. Large-scale, long-term randomized controlled trials in adults using current compounded sermorelin formulations are lacking.
Stacking
Combining a GHRH analog like sermorelin with a growth hormone-releasing peptide (GHRP) that acts on the ghrelin receptor produces a synergistic effect that exceeds the GH output of either compound alone. This occurs because the two peptides act on different receptor pathways that converge on the somatotroph cell.
Sermorelin + Ipamorelin
The most widely prescribed combination. Sermorelin provides the GHRH signal while ipamorelin activates the ghrelin/GHS-R1a pathway, creating a dual stimulus on pituitary somatotrophs. Ipamorelin is preferred over older GHRPs because it does not significantly elevate cortisol, prolactin, or appetite. A common protocol uses sermorelin 200 to 300 mcg + ipamorelin 200 to 300 mcg, administered together subcutaneously at bedtime.
Sermorelin + GHRP-6
An older combination that produces robust GH release. Research has demonstrated that co-administration of GHRH with GHRP-2 (a closely related peptide) produced a synergistic 54-fold increase in pulsatile GH secretion compared to baseline in one study. GHRP-6 is effective but less selective than ipamorelin. It increases cortisol and prolactin to a greater degree and stimulates appetite through ghrelin receptor activation, which may be desirable or undesirable depending on the patient's goals.
Sermorelin + CJC-1295
Since both are GHRH analogs acting on the same receptor pathway, combining them does not produce the same synergistic effect as pairing with a GHRP. However, some protocols use sermorelin for its acute pulsatile effect alongside CJC-1295 (no DAC) to provide additional GHRH receptor occupancy with a slightly different pharmacokinetic profile. This combination is less common and less evidence-based than GHRH + GHRP stacks.
Reconstitution, Storage & Prep
Sermorelin is supplied as a lyophilized (freeze-dried) powder in sterile vials, typically in 2 mg, 3 mg, or 5 mg quantities. It requires reconstitution before use.
Reconstitution Process:
- Remove the sermorelin vial and bacteriostatic water from the refrigerator and allow both to reach room temperature (5 to 10 minutes)
- Wipe the rubber stopper of each vial with a sterile alcohol swab
- Using a sterile syringe, draw the appropriate volume of bacteriostatic water
- Insert the needle into the sermorelin vial and inject the water slowly against the glass wall, allowing it to run down gently. Never spray directly onto the powder
- Swirl the vial gently until the powder is fully dissolved. Never shake, as this can denature the peptide
- The solution should be clear and colorless; discard if cloudy or if particulate matter is visible
Common reconstitution ratio: 3 mg + 3 mL bacteriostatic water = 1 mg/mL (1,000 mcg/mL). For a 300 mcg dose at this concentration, draw 0.3 mL (30 units on a standard insulin syringe).
Storage Guidelines:
- Unreconstituted powder: Stable at room temperature; refrigeration at 2 to 8°C (36 to 46°F) is recommended for long-term storage (12+ months)
- Reconstituted solution: Must be refrigerated at 2 to 8°C (36 to 46°F); use within 4 to 6 weeks when reconstituted with bacteriostatic water
- Never freeze reconstituted sermorelin. Ice crystal formation can permanently damage the peptide's tertiary structure
- Temperature excursions: If left at room temperature for more than 72 hours after reconstitution, the vial should be discarded
- Protect from light and heat at all times
- Always use bacteriostatic water (containing 0.9% benzyl alcohol) rather than sterile water for multi-dose vials to prevent bacterial contamination
Side Effects
Sermorelin has a well-established safety profile from its years as an FDA-approved medication. The following adverse effects have been reported in clinical trials and post-marketing experience:
Common (typically mild and self-limiting):
- Injection site reactions: pain, redness, swelling, or itching at the injection site, the most frequently reported adverse event in clinical studies
- Facial flushing: a brief warm, red sensation in the face and neck, typically resolving within 5 to 20 minutes post-injection
- Headache: mild headache reported in a subset of patients, most commonly during the first 1 to 2 weeks of therapy
- Dizziness or lightheadedness, particularly with initial doses
Less common:
- Nausea
- Drowsiness or restlessness
- Transient urticaria (hives)
- Mild water retention
- Difficulty swallowing (reported rarely with the injectable form)
- Altered taste perception
Rare but clinically significant:
- Hypersensitivity reactions: severe allergic symptoms including facial swelling, difficulty breathing, or anaphylaxis. These require immediate medical attention
- Antibody formation: a large proportion of pediatric patients in clinical trials developed anti-sermorelin antibodies at least once during treatment, though antibody presence at one assessment often became negative by the next and did not appear to affect growth outcomes in most cases
Precautions and contraindications:
- Active malignancy (GH and IGF-1 may promote growth of existing tumors)
- Hypothyroidism should be corrected before initiating therapy, as low thyroid function impairs GH response
- Concomitant glucocorticoid therapy may attenuate sermorelin's effects
- Obese patients may have blunted GH responses to sermorelin
Legal Status / FDA
Sermorelin's regulatory history is unique among peptides in the anti-aging space. Unlike most peptides prescribed through compounding pharmacies, sermorelin was once a fully FDA-approved medication with a completed New Drug Application, clinical trial data, and an established safety profile.
FDA timeline:
- 1988: FDA orphan drug designation for idiopathic/organic GH deficiency in children
- December 1990: NDA 19-863 approved (sermorelin injection 0.05 mg/amp for diagnostic use)
- September 1997: NDA 20-443 approved (Geref, 0.5 mg and 1.0 mg vials, for treatment of pediatric GHD)
- December 2008: EMD Serono notifies FDA of voluntary discontinuation due to commercial reasons
- June 2009: FDA formally withdraws NDA approval
- March 2013: FDA publishes determination in the Federal Register confirming that Geref "was not withdrawn from sale for reasons of safety or effectiveness"
This 2013 determination is significant because it enables sermorelin to be legally compounded. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies may prepare sermorelin on a per-prescription basis for individual patients when prescribed by a licensed provider. Section 503B outsourcing facilities may also compound sermorelin under FDA oversight. The active pharmaceutical ingredient must be pharmaceutical-grade and sourced from FDA-registered suppliers with a valid Certificate of Analysis.
Sermorelin is not a controlled substance in the United States and does not appear on the DEA's schedules. However, it is a prescription medication. It cannot be legally sold over the counter, as a dietary supplement, or marketed for human use without a valid prescription.
Sports / WADA
Sermorelin is explicitly prohibited by the World Anti-Doping Agency (WADA) under Section S2.2 of the Prohibited List: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. Specifically, it falls under S2.2.4 as a growth hormone-releasing hormone (GHRH) analog, listed alongside other GHRH analogs including CJC-1295 and tesamorelin.
The prohibition applies at all times, both in-competition and out-of-competition. All growth hormone secretagogues, including GHS-R agonists (ipamorelin, ibutamoren) and GHRH analogs (sermorelin, CJC-1295, tesamorelin), are banned based on their capacity to elevate GH and IGF-1 levels, which may enhance muscle mass, reduce fat mass, and accelerate recovery.
Athletes subject to WADA, USADA, or other anti-doping organization testing face sanctions if sermorelin or its metabolites are detected. A Therapeutic Use Exemption (TUE) is theoretically available but exceedingly difficult to obtain for S2 substances. Competitive athletes in any tested sport should consider sermorelin use a disqualifying violation.
Conclusion
Sermorelin occupies a distinctive position among growth hormone secretagogues. As the biologically active fragment of native GHRH with a completed history of FDA approval, it offers a level of clinical validation that few other peptides in the anti-aging and performance space can claim. Its mechanism of action, stimulating the pituitary through the same receptor as endogenous GHRH while preserving natural feedback loops, represents a fundamentally different approach from exogenous growth hormone administration. The short half-life that may appear to be a limitation actually serves a physiological advantage: it produces brief, pulsatile GH release that mirrors the body's own secretory pattern.
The evidence base, while stronger than that of many other peptides, has limitations. Pediatric GHD data is robust, but adult anti-aging applications rest on smaller, shorter studies with surrogate endpoints. Patients considering sermorelin should set realistic expectations, understand that results develop gradually over months, and recognize that individual responses vary substantially based on age, baseline hormone status, and lifestyle factors.
As with any hormone-modulating therapy, sermorelin should be used under the guidance of a qualified healthcare provider who can assess candidacy, monitor IGF-1 and other relevant biomarkers, and adjust dosing based on clinical response. When sourced from a licensed compounding pharmacy and prescribed appropriately, sermorelin represents one of the better-studied tools available for supporting age-related growth hormone decline.